Profiles

Glenn Jacobson

Professor Glenn Jacobson

Glenn Jacobson

Head of School, Pharmacy and Pharmacology

Room 4016 , Pharmacy Building

+61 3 6226 2202 (phone)

+61 3 6226 2870 (fax)

Glenn.Jacobson@utas.edu.au

Dr Glenn Jacobson is a Senior Lecturer in Pharmaceutics and Toxicology at the School of Medicine. His main research area involves studying the pharmacodynamic and pharmacokinetic aspects of beta2-agonist enantiomers (non-superimposable mirror images called stereoisomers) and their role in both asthma and muscle performance by using technically advanced stereoselective chromatography assays. His sports doping research is internationally funded by the World Anti-Doping Agency.

Biography

Dr Jacobson completed a PhD in pharmacy in 1996 in the area of airways disease pharmacotherapy. Dr Jacobson's research focus is clinical pharmaceutics with a strong emphasis on bio-analytical applications, particularly chiral beta2-agonists, utilising LC-MS/MS. His previous experience includes pharmaceutical industry and commercial laboratory roles in Australia and Europe, undertaking Phase III international clinical trial laboratory data management.

Dr Jacobson has undertaken pharmaceutical industry contract research in the area of analytical applications for novel veterinary drug delivery research and 'chiral switch' beta2 agonist food supplementation for animal production both locally and with US collaborators. He has extensive knowledge of analytical techniques, applications, and methodology for assay quality assurance, including familiarity with ICH and FDA guidance documentation (some of Dr Jacobson's work on low molecular weight heparin analysis has been cited by the FDA in guidance documentation and has led to product recalls in North America).

Dr Jacobson has leading international expertise in enantioselective analysis of beta2-agonists in a range of tissues with applications to anti-doping research and therapeutics in the area of respiratory medicine, muscle wasting disease and cardiac function. Dr Jacobson has a 40% undergraduate teaching load within the areas of pharmaceutics and toxicology, and is currently supervising four PhD students in projects relating to application of analytical instrumentation in natural products research/drug discovery, and has been primary supervisor for eight RHD completions since 2008.

Career summary

Qualifications

PhD, University of Tasmania, Australia, 1996. Thesis: Aspects of the pharmacotherapy of Airways Diseases
BPharm(Hons), University of Tasmania, Australia. 1991
BPharm, University of Tasmania, Australia. 1990

Administrative expertise

Dr Jacobson has experience in GCP compliance and has current GCP certification, with particularly expertise in clinical data management, CRF design, GLP and bio-analytical procedure validation.

Dr Jacobson has a 20% administrative load consisting of unit administration for second and third year pharmaceutics and toxicology, and is currently second year coordinator of the BPharm program. Dr Jacobson has previously held the position of Deputy Head of School (Pharmacy) 2009-11, and non-professorial elected member for Academic Senate (2010-11).

He also sits on the Central Science Laboratory Users Group (2008-) and is a member of the Tasmania Health and Medical Human Research Ethics Committee (IRB) (2015-).

Teaching

toxicology, clinical toxicology, pharmaceutics, drug delivery, drug discovery, drug stability, drug analysis, enantiomer, chiral.

Teaching expertise

Dr Jacobson has particular teaching expertise in the drug sciences, namely pharmaceutics (the science of drug delivery which focuses on physicochemical properties of drugs and their delivery systems and how these properties relate to effectively getting a drug to the site of action in the body) and clinical toxicology.

He has developed and taught the current pharmaceutical science and toxicology units, in line with current BPharm professional competency standards. Dr Jacobson has previously co-developed a Masters coursework program (MPharmSc) within the Division of Pharmacy, and was previously coordinator for the BPharm(Hons) program where he developed Honours assessment rubrics.

Teaching responsibility

Pharmaceutical Science and Practice 2A (CSA255)
Pharmaceutical Science A (CSA257)
Pharmaceutical Science B (CSA258)
Toxicology (CSA331)
Toxicology (CSA332)
Toxicology (CSA333)

View more on Professor Glenn Jacobson in WARP

Expertise

Dr Jacobson's research focus is clinical pharmaceutics with a strong emphasis on bio-analytical applications, particularly chiral beta2-agonists, utilising LC-MS/MS. His previous experience includes pharmaceutical industry and commercial laboratory roles in Australia and Europe, undertaking Phase III international clinical trial laboratory data management.

He has extensive knowledge of analytical techniques, applications, and methodology for assay quality assurance, including familiarity with ICH and FDA guidance documentation (some of Dr Jacobson's work on low molecular weight heparin analysis has been cited by the FDA in guidance documentation and has led to product recalls in North America). He has undertaken industry consultancies involved with the chemical characterisation and synthesis of previously unidentified impurities in pharmaceutical products for regulatory compliance.

Research Themes

Dr Jacobson's beta2-agonist research aligns to the University's research theme of Better Health, and lies in the Faculty of Health research theme of Chronic Health. Asthma and Chronic Obstructive Pulmonary Disease (COPD) leads to significant morbidity and mortality in the community.

The use of beta2-agonists is a cornerstone of treatment, however, these drugs although very safe and effective if used appropriately, have been associated with worsening asthma control and some paradoxical deaths.

There are some concerns that part of the problem may be due to the medications being used as racemic mixtures of stereoisomers, where one isomer is pharmacologically active, and the other may actually lead to increased bronchial hyper-responsiveness.

It is not known if there are differences in the bronchopulmonary pharmacokinetics (time course of drug in the lung) between enantiomers, and whether this may lead to worsening bronchodilatory function in some individuals with asthma or COPD. It is also unclear if genetics is a determinant of differences in uptake and metabolism between patients.

Collaboration

Dr Jacobson is a member of the 'Breathe Well' CRE and has local collaborations within the Menzies Institute for Medical Research (Blood Pressure Research Group and the Muscle Metabolism Group), with work in the area of asthma, COPD and smoking studies related to beta2-agonists, as well as genetic determinants of Phase 1 and Phase 2 metabolism and flavonoid effects on muscle.

He also collaborates with research groups at the Sackler Institute (Kings College, UK), University of Otago (NZ), and University of Copenhagen with regard to enantioselective beta2-agonist analyses and applications in respiratory and doping research. Dr Jacobson is currently involved in development of novel bronchopulmonary sampling techniques to measure enantioselective deposition and uptake in a horse model with collaborators in the School of Animal and Veterinary Sciences at Charles Sturt University, along with other chiral veterinary drug projects.

Awards

University of Tasmania, Business Competition Grant (2008) for commercialisation of research

Current projects

Enantioselective pharmacokinetics of salbutamol and application to doping control
Effect of oral and inhaled salbutamol on muscle performance, exhaled gases, cardiac physiology using pulse wave analysis, and airway flow volume
Enantioselective pharmacokinetics of formoterol and application to doping control
Effect of oral and inhaled formoterol on muscle performance, exhaled gases, cardiac physiology using pulse wave analysis, and airway flow volume
Assay development and enantioselective pharmacokinetics of formoterol in urine.
Enantioselective pharmacokinetics of salmeterol in urine
Enantioselective bronchopulmonary pharmacokinetics of salbutamol in a horse model using direct epithelial lining fluid (ELF) over time via direct swab sampling, central and peripheral lung tissue (via endoscopic bronchial biopsy and percutaneous pulmonary biopsy respectively)
Relationship between cardiac markers and salbutamol plasma levels in COPD patients.
Enantioselective pharmacodynamic/pharmacokinetic relationship for the alpha2-agonist medetomidine in dog pre-anaesthesia
Development of a zebrafish pericardial oedema model and measurement of cardiac physiology
Characterisation and biological effect of novel flavonoids on microvascular uptake and blood glucose

Fields of Research

Pharmaceutical sciences (321405)
Pharmacology and pharmaceutical sciences (321499)
Clinical pharmacology and therapeutics (321402)
Epidemiology (420299)
Basic pharmacology (321401)
Preventative health care (420605)
Cardiology (incl. cardiovascular diseases) (320101)
Health services and systems (420399)
Toxicology (incl. clinical toxicology) (321407)
Veterinary pharmacology (300911)
Respiratory diseases (320103)
Medical biochemistry - carbohydrates (320502)
Primary health care (420319)
Animal protection (incl. pests and pathogens) (300304)
Animal growth and development (300301)
Biologically active molecules (340401)
Anaesthesiology (320201)
Neurosciences (320999)
Gene expression (incl. microarray and other genome-wide approaches) (310505)
Paediatrics (321399)
Medical biochemistry - proteins and peptides (incl. medical proteomics) (320506)
Nutrition and dietetics (321099)
Separation science (340109)
Medical infection agents (incl. prions) (320702)
Veterinary parasitology (300909)
Podiatry (420107)
Instrumental methods (excl. immunological and bioassay methods) (340105)
Agronomy (300403)
Aboriginal and Torres Strait Islander medicine and treatments (450411)
Agricultural biotechnology (300199)
Plant physiology (310806)
Gastroenterology and hepatology (320209)
Oncology and carcinogenesis (321199)
Medicinal and biomolecular chemistry (340499)
Medical microbiology (320799)
Sports medicine (320225)
Infectious diseases (320211)
Dermatology (320205)
Rheumatology and arthritis (320223)
Analytical chemistry (340199)
Systems physiology (320803)
Bioassays (340102)
Nutritional science (321004)
Clinical pharmacy and pharmacy practice (321403)
Proteomics and intermolecular interactions (excl. medical proteomics) (310109)
Exploration geochemistry (370301)
Tumour immunology (320409)
Medical biochemistry and metabolomics (320599)
Cancer therapy (excl. chemotherapy and radiation therapy) (321104)
Pharmacogenomics (321406)
Pathology (excl. oral pathology) (320220)
Sports science and exercise (420799)
Agricultural land management (300202)
Orthopaedics (320216)
Dental therapeutics, pharmacology and toxicology (320303)
Crop and pasture biomass and bioproducts (300405)
Cell physiology (320801)
Analytical spectrometry (340101)
Medical biotechnology (320699)
Occupational and workplace health and safety (350505)
Veterinary medicine (excl. urology) (300907)
Veterinary bacteriology (300903)
Agricultural biotechnology diagnostics (incl. biosensors) (300101)
Organometallic chemistry (340209)
Crop and pasture production (300499)
Otorhinolaryngology (320217)
Neurology and neuromuscular diseases (320905)
Cancer cell biology (321101)
Traditional, complementary and integrative medicine (420899)
Biochemistry and cell biology (310199)
Genetics (310599)
Crop and pasture improvement (incl. selection and breeding) (300406)
Health promotion (420603)

Research Objectives

Clinical health (200199)
Other health (209999)
Diagnosis of human diseases and conditions (200101)
Public health (excl. specific population health) (200499)
Preventive medicine (200412)
Health related to ageing (200502)
Beef cattle (100401)
Fisheries - aquaculture (100299)
Other plant production and plant primary products (269999)
Treatment of human diseases and conditions (200105)
Allied health therapies (excl. mental health services) (200301)
Animal welfare (109902)
Expanding knowledge in the biological sciences (280102)
Human pharmaceutical products (240899)
Human pharmaceutical treatments (240803)
Health status (incl. wellbeing) (200407)
Nutrition (200410)
Efficacy of medications (200102)
Deer (100403)
Environmentally sustainable plant production (260199)
Organised sports (130602)
Veterinary biological preventatives (241601)
Expanding knowledge in the environmental sciences (280111)
Poultry (100411)
Sport, exercise and recreation (130699)
Pasture, browse and fodder crops (100599)
Evaluation of health and support services (200299)
Veterinary pharmaceutical treatments (241603)
Neonatal and child health (200506)
Fresh fruits and vegetables (post harvest) (260402)
Pigs (100410)
Rural and remote area health (200508)
Sugar cane (cut for crushing) (260403)
Mineral exploration (250399)
Inpatient hospital care (200304)
Evaluation of health outcomes (200202)
Social structure and health (200207)
Scientific instruments (241003)
Plastics (240910)
Field grown vegetable crops (260505)
Human diagnostics (240802)
Expanding knowledge in the health sciences (280112)
Health education and promotion (200203)

Publications

Dr Jacobson has been working in the area of stereoselective analyses of beta2-agonists since 2003, with accelerated impact in this area over the last 5 years made possible due to generational advances in UPLC-MS/MS instrumentation. Dr Jacobson's work includes the first studies demonstrating stereoselective uptake of salbutamol into tissue. To-date, this work has resulted in over 350 non-self-citations with an h-index of 10.

Total publications

142

Highlighted publications

(5 outputs)

Year	Type	Citation
2017	Journal Article	Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Walters EH, 'Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control', Drug Testing and Analysis, 9, (8) pp. 1262-1266. ISSN 1942-7611 (2017) [Refereed Article] DOI: 10.1002/dta.2131 [eCite] [Details] Citations: Scopus - 13Web of Science - 13 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2017	Journal Article	Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, et al., 'Bronchopulmonary pharmacokinetics of (R)- salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses', British Journal of Clinical Pharmacology, 83, (7) pp. 1436-1445. ISSN 0306-5251 (2017) [Refereed Article] DOI: 10.1111/bcp.13228 [eCite] [Details] Citations: Scopus - 15Web of Science - 12 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2017	Journal Article	Onslev J, Jacobson G, Narkowicz C, Backer V, Kalsen A, et al., 'Beta₂‑adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men', European Journal of Applied Physiology, 117, (9) pp. 1907-1915. ISSN 1439-6319 (2017) [Refereed Article] DOI: 10.1007/s00421-017-3679-9 [eCite] [Details] Citations: Scopus - 19Web of Science - 19 Co-authors: Narkowicz C Tweet
2016	Journal Article	Jacobson GA, Fawcett JP, 'Beta2-agonist doping control and optical isomer challenges', Sports Medicine, 46, (12) pp. 1787-1795. ISSN 0112-1642 (2016) [Refereed Article] DOI: 10.1007/s40279-016-0547-4 [eCite] [Details] Citations: Scopus - 16Web of Science - 15 Tweet
2015	Journal Article	Jacobson GA, Yee KC, Wood-Baker R, Walters EH, 'SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: Are some athletes at risk of higher urine levels?', Drug testing and analysis, 7 Article 1645. ISSN 1942-7611 (2015) [Refereed Article] DOI: 10.1002/dta.1645 [eCite] [Details] Citations: Scopus - 20Web of Science - 22 Co-authors: Yee KC; Wood-Baker R; Walters EH Tweet

Journal Article

(80 outputs)

Year	Citation	Altmetrics
2022	Chhetri J, Dilek J, Davies NW, Jacobson GA, Dallmann R, et al., 'NQO1 protects against clioquinol toxicity', Frontiers in Pharmacology, 13 Article 1000278. ISSN 1663-9812 (2022) [Refereed Article] DOI: 10.3389/fphar.2022.1000278 [eCite] [Details] Co-authors: Chhetri J; Davies NW; Guven N Tweet
2021	Breenfeldt Andersen A, Jacobson GA, Bejder J, Premilovac D, Richards SM, et al., 'An abductive inference approach to assess the performance‑enhancing effects of drugs included on the World Anti‑Doping Agency Prohibited List', Sports Medicine ISSN 0112-1642 (2021) [Refereed Article] DOI: 10.1007/s40279-021-01450-9 [eCite] [Details] Citations: Scopus - 3Web of Science - 5 Co-authors: Premilovac D; Richards SM Tweet
2021	Eibye K, Jacobson GA, Bengtsen K, Jessen S, Backer V, et al., 'Effect of one-week oral or inhaled salbutamol treatment with washout on repeated sprint performance in trained subjects', Translational Sports Medicine, 4 pp. 241-249. ISSN 2573-8488 (2021) [Refereed Article] DOI: 10.1002/tsm2.210 [eCite] [Details] Tweet
2021	Hostrup M, Jessen S, Backer V, Bangsbo J, Jacobson GA, 'Beta 2 -adrenergic agonists can enhance intense performance and muscle strength in healthy individuals', Allergy: European Journal of Allergy and Immunology ISSN 0105-4538 (2021) [Letter or Note in Journal] DOI: 10.1111/all.14735 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Tweet
2021	Ishaq M, Tran DT, Wu Y, Nowak K, Deans BJ, et al., 'Asperuloside enhances taste perception and prevents weight gain in high-fat fed mice', Frontiers in Endocrinology, 12 pp. 1-11. ISSN 1664-2392 (2021) [Refereed Article] DOI: 10.3389/fendo.2021.615446 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Ishaq M; Tran DT; Wu Y; Deans BJ; Southam B; Vicenzi S; Randall C; Yang C; Tan E; Ahmad T; Shastri M; Bleasel M; Scowen P; Bissember AC; Smith JA; Eri R; Canales J; Iglesias M; Guven N; Caruso V Tweet
2021	Wise JC, Hughes KJ, Edwards S, Jacobson GA, Narkowicz CK, et al., 'Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses', Journal of Veterinary Internal Medicine, 35, (1) pp. 620-631. ISSN 0891-6640 (2021) [Refereed Article] DOI: 10.1111/jvim.15971 [eCite] [Details] Citations: Scopus - 1Web of Science - 2 Co-authors: Narkowicz CK Tweet
2020	Gupta A, Narkowicz CK, Al-Aubaidy HA, Jelinek HF, Nichols DS, et al., 'Phytosterol supplements do not inhibit dipeptidyl peptidase-4', Diabetes & Metabolic Syndrome: clinical research & reviews, 14 pp. 1475-1478. ISSN 1871-4021 (2020) [Refereed Article] DOI: 10.1016/j.dsx.2020.07.019 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Gupta A; Narkowicz CK; Al-Aubaidy HA; Nichols DS; Burgess JR Tweet
2020	Hostrup M, Jacobson GA, Jessen S, Krogh Lemminger A, 'Anabolic and lipolytic actions of beta₂-agonists in humans and antidoping challenges', Drug Testing and Analysis, 12, (5) pp. 597-609. ISSN 1942-7603 (2020) [Refereed Article] DOI: 10.1002/dta.2728 [eCite] [Details] Citations: Scopus - 20Web of Science - 19 Tweet
2020	Jacobson GA, Hostrup M, 'The salmeterol anomaly and the need for a urine threshold', Drug Testing and Analysis ISSN 1942-7603 (2020) [Refereed Article] DOI: 10.1002/dta.2810 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Tweet
2020	Jessen S, Solheim SA, Jacobson GA, Eibye K, Bangsbo J, et al., 'Beta₂ -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men', Drug Testing and Analysis, 12, (5) pp. 610-618. ISSN 1942-7603 (2020) [Refereed Article] DOI: 10.1002/dta.2755 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 Tweet
2020	Johnstone LK, Bereznicki BJ, Jacobson G, Thompson AJ, 'Implementation of mouth rinsing after use of inhaled corticosteroids in Australia', International Journal of Clinical Pharmacy ISSN 2210-7703 (2020) [Refereed Article] DOI: 10.1007/s11096-020-01161-7 [eCite] [Details] Co-authors: Bereznicki BJ; Thompson AJ Tweet
2019	Calzetta L, Crupi R, Roncada P, Pistocchini E, di Cave D, et al., 'Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference', Equine Veterinary Journal pp. 1-9. ISSN 0425-1644 (2019) [Refereed Article] DOI: 10.1111/evj.13137 [eCite] [Details] Citations: Scopus - 3Web of Science - 4 Tweet
2019	Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Walters EH, 'Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control', Drug Testing and Analysis, 11, (7) pp. 950-956. ISSN 1942-7603 (2019) [Refereed Article] DOI: 10.1002/dta.2587 [eCite] [Details] Citations: Scopus - 10Web of Science - 9 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2019	Morton H, Narkowicz CK, Habib S, Nichols DS, Jacobson GA, 'Beta₂-adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular protein kinase A-signalling at therapeutic inhaled doses', Drug Testing and Analysis, 11, (7) pp. 1048-1056. ISSN 1942-7603 (2019) [Refereed Article] DOI: 10.1002/dta.2580 [eCite] [Details] Citations: Scopus - 6Web of Science - 5 Co-authors: Narkowicz CK; Nichols DS Tweet
2019	Scrimgeour S, Nunan M, Sanburg ALC, Jones A, Narkowicz C, et al., 'Pharmaceutical quality of antibiotics in Small Island Nations in the Western Pacific region: a pilot survey', Journal of Pharmacy Practice and Research, 49, (5) pp. 426-432. ISSN 1445-937X (2019) [Refereed Article] DOI: 10.1002/jppr.1540 [eCite] [Details] Citations: Scopus - 1 Co-authors: Narkowicz C Tweet
2018	Gupta A, Jacobson GA, Burgess JR, Jelinek HF, Nichols DS, et al., 'Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications', Biochemical and Biophysical Research Communications, 503, (1) pp. 21-25. ISSN 0006-291X (2018) [Refereed Article] DOI: 10.1016/j.bbrc.2018.04.156 [eCite] [Details] Citations: Scopus - 18Web of Science - 16 Co-authors: Gupta A; Burgess JR; Nichols DS; Narkowicz CK; Al-Aubaidy HA Tweet
2018	Hostrup M, Onslev J, Jacobson G, Wilson R, Bangsbo J, 'Chronic β₂-adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men', Journal of Physiology, 596, (2) pp. 231-252. ISSN 0022-3751 (2018) [Refereed Article] DOI: 10.1113/JP274970 [eCite] [Details] Citations: Scopus - 29Web of Science - 26 Co-authors: Wilson R Tweet
2018	Hostrup M, Reitelseder S, Jessen S, Kalsen A, Nyberg M, et al., 'Beta₂-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men', Journal of Physiology, 596, (17) pp. 4121-4139. ISSN 0022-3751 (2018) [Refereed Article] DOI: 10.1113/JP275560 [eCite] [Details] Citations: Scopus - 29Web of Science - 25 Tweet
2018	Jacobson GA, Raidal S, Hostrup M, Calzetta L, Wood-Baker R, et al., 'Long-acting β2-agonists in asthma: enantioselective safety studies are needed', Drug Safety, 41, (5) pp. 441-449. ISSN 0114-5916 (2018) [Refereed Article] DOI: 10.1007/s40264-017-0631-1 [eCite] [Details] Citations: Scopus - 9Web of Science - 8 Co-authors: Wood-Baker R; Walters EH Tweet
2018	Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, et al., 'Salmeterol undergoes enantioselective bronchopulmonary distribution with receptor localisation a likely determinant of duration of action', Journal of Pharmaceutical and Biomedical Analysis, 154 pp. 102-107. ISSN 0731-7085 (2018) [Refereed Article] DOI: 10.1016/j.jpba.2018.02.048 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2018	Shafuddin E, Chang CL, Cooray M, Tuffery CM, Hopping SJ, et al., 'Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease', Respiratory Medicine, 145 pp. 192-199. ISSN 0954-6111 (2018) [Refereed Article] DOI: 10.1016/j.rmed.2018.11.008 [eCite] [Details] Citations: Scopus - 10Web of Science - 11 Tweet
2017	Cui H, King AE, Jacobson GA, Small DH, 'Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice', Journal of Neuroscience Research, 95, (4) pp. 992-999. ISSN 0360-4012 (2017) [Refereed Article] DOI: 10.1002/jnr.23880 [eCite] [Details] Citations: Scopus - 5Web of Science - 3 Co-authors: Cui H; King AE; Small DH Tweet
2017	Edwards SH, Khalfan SA, Jacobson GA, Pirie AD, Raidal SL, 'Pharmacokinetics of intravenous continuous rate infusions of sodium benzylpenicillin 2 and ceftiofur sodium in adult horses', American Journal of Veterinary Research, 78, (1) pp. 17-26. ISSN 0002-9645 (2017) [Refereed Article] DOI: 10.2460/ajvr.78.1.17 [eCite] [Details] Citations: Scopus - 1Web of Science - 2 Co-authors: Pirie AD Tweet
2017	Jacobson GA, Hostrup M, 'Terbutaline: level the playing field for inhaled β₂-agonists by introducing a dosing and urine threshold', British Journal of Sports Medicine, 51 pp. 1323-1324. ISSN 0306-3674 (2017) [Contribution to Refereed Journal] DOI: 10.1136/bjsports-2016-096453 [eCite] [Details] Citations: Scopus - 10Web of Science - 9 Tweet
2017	Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Walters EH, 'Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control', Drug Testing and Analysis, 9, (8) pp. 1262-1266. ISSN 1942-7611 (2017) [Refereed Article] DOI: 10.1002/dta.2131 [eCite] [Details] Citations: Scopus - 13Web of Science - 13 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2017	Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, et al., 'Bronchopulmonary pharmacokinetics of (R)- salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses', British Journal of Clinical Pharmacology, 83, (7) pp. 1436-1445. ISSN 0306-5251 (2017) [Refereed Article] DOI: 10.1111/bcp.13228 [eCite] [Details] Citations: Scopus - 15Web of Science - 12 Co-authors: Narkowicz CK; Nichols DS; Walters EH Tweet
2017	Lu W, Chappell KJ, Walters JAE, Jacobson GA, Patel R, et al., 'The effect of varenicline and nicotine patch on smoking rate and satisfaction with smoking: an examination of the mechanism of action of two pre-quit pharmacotherapies', Psychopharmacology, 234, (13) pp. 1969-1976. ISSN 0033-3158 (2017) [Refereed Article] DOI: 10.1007/s00213-017-4604-y [eCite] [Details] Citations: Scopus - 5Web of Science - 7 Co-authors: Lu W; Chappell KJ; Walters JAE; Patel R; Schuz N; Ferguson SG Tweet
2017	Onslev J, Jacobson G, Narkowicz C, Backer V, Kalsen A, et al., 'Beta₂‑adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men', European Journal of Applied Physiology, 117, (9) pp. 1907-1915. ISSN 1439-6319 (2017) [Refereed Article] DOI: 10.1007/s00421-017-3679-9 [eCite] [Details] Citations: Scopus - 19Web of Science - 19 Co-authors: Narkowicz C Tweet
2016	Jacobson GA, Fawcett JP, 'Beta2-agonist doping control and optical isomer challenges', Sports Medicine, 46, (12) pp. 1787-1795. ISSN 0112-1642 (2016) [Refereed Article] DOI: 10.1007/s40279-016-0547-4 [eCite] [Details] Citations: Scopus - 16Web of Science - 15 Tweet
2016	Lu W, Ferguson SG, Nichols DS, Patel R, Jacobson GA, 'Application of an assay for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in urine for the assessment of tobacco-related harm', Journal of Pharmaceutical and Biomedical Analysis, 131 pp. 327-332. ISSN 0731-7085 (2016) [Refereed Article] DOI: 10.1016/j.jpba.2016.08.013 [eCite] [Details] Citations: Scopus - 4Web of Science - 3 Co-authors: Lu W; Ferguson SG; Nichols DS; Patel R Tweet
2016	Obaid NA, Tristram S, Narkowicz CK, Jacobson GA, 'Reliability of Haemophilus influenzae biofilm measurement via static method, and determinants of in vitro biofilm production', Canadian Journal of Microbiology, 62, (12) pp. 1013-1020. ISSN 0008-4166 (2016) [Refereed Article] DOI: 10.1139/cjm-2016-0228 [eCite] [Details] Co-authors: Tristram S; Narkowicz CK Tweet
2015	Jacobson GA, Yee KC, Wood-Baker R, Walters EH, 'SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: Are some athletes at risk of higher urine levels?', Drug testing and analysis, 7 Article 1645. ISSN 1942-7611 (2015) [Refereed Article] DOI: 10.1002/dta.1645 [eCite] [Details] Citations: Scopus - 20Web of Science - 22 Co-authors: Yee KC; Wood-Baker R; Walters EH Tweet
2015	Lu W, Ferguson SG, Nichols D, Patel R, Jacobson GA, 'Determination of nicotine in cartridge-based electronic cigarettes', Analytical Letters, 48, (17) pp. 2715-2722. ISSN 0003-2719 (2015) [Refereed Article] DOI: 10.1080/00032719.2015.1048349 [eCite] [Details] Citations: Scopus - 4Web of Science - 5 Co-authors: Lu W; Ferguson SG; Nichols D; Patel R Tweet
2015	Obaid NA, Jacobson GA, Tristram S, 'Relationship between clinical site of isolation and ability to form biofilms in vitro in nontypeable Haemophilus influenzae', Canadian Journal of Microbiology, 61, (3) pp. 243-245. ISSN 0008-4166 (2015) [Refereed Article] DOI: 10.1139/cjm-2014-0763 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Tristram S Tweet
2015	Thomas J, Narkowicz CK, Jacobson GA, Peterson GM, 'Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial', Journal of Clinical Pharmacy and Therapeutics, 40, (5) pp. 566-572. ISSN 0269-4727 (2015) [Refereed Article] DOI: 10.1111/jcpt.12311 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Narkowicz CK; Peterson GM Tweet
2014	Chhetri J, Jacobson G, Gueven N, 'Zebrafish - on the move towards ophthalmological research', Eye, 28 pp. 367-380. ISSN 0950-222X (2014) [Refereed Article] DOI: 10.1038/eye.2014.19 [eCite] [Details] Citations: Scopus - 88Web of Science - 81 Co-authors: Chhetri J; Gueven N Tweet
2014	Jacobson GA, Ferguson SG, 'Relationship between cotinine and trans-3' -hydroxycotinine glucuronidation and the nicotine metabolite ratio in Caucasian smokers', Biomarkers, 19, (8) pp. 679-683. ISSN 1366-5804 (2014) [Refereed Article] DOI: 10.3109/1354750X.2014.966254 [eCite] [Details] Citations: Scopus - 5Web of Science - 4 Co-authors: Ferguson SG Tweet
2014	Jacobson GA, Pirie A, Edwards S, Hughes KJ, Rendle DI, et al., 'Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications', Journal of Pharmaceutical and Biomedical Analysis, 94 pp. 54-57. ISSN 0731-7085 (2014) [Refereed Article] DOI: 10.1016/j.jpba.2014.01.016 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Pirie A; Davies NW Tweet
2014	Pirie AD, Davies NW, Ahuja KDK, Adams MJ, Shing CM, et al., 'Hypolipidaemic effect of crude extract from Carpobrotus rossii (pigface) in healthy rats', Food and Chemical Toxicology, 66 pp. 134-139. ISSN 0278-6915 (2014) [Refereed Article] DOI: 10.1016/j.fct.2014.01.034 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Pirie AD; Davies NW; Ahuja KDK; Adams MJ; Shing CM; Narkowicz C; Geraghty DP Tweet
2014	Shastri M, Lu W, Ferguson SG, Narkowicz CK, Davies NW, et al., 'Determination of cotinine, 3'-hydroxycotinine, and their glucuronides in urine by ultra-high performance liquid chromatography', Analytical Letters, 48, (8) pp. 1217-1233. ISSN 0003-2719 (2014) [Refereed Article] DOI: 10.1080/00032719.2014.979363 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Shastri M; Lu W; Ferguson SG; Narkowicz CK; Davies NW Tweet
2013	Cui H, Freeman C, Jacobson GA, Small DH, 'Proteoglycans in the central nervous system: Role in development, neural repair, and Alzheimer's disease', IUBMB Life, 65, (2) pp. 108-120. ISSN 1521-6543 (2013) [Refereed Article] DOI: 10.1002/iub.1118 [eCite] [Details] Citations: Scopus - 64Web of Science - 61 Co-authors: Cui H; Small DH Tweet
2013	Jacobson GA, Yee KC, Premilovac D, Rattigan S, 'Enantioselective disposition of (R/S)-albuterol in skeletal and cardiac muscle', Drug Testing and Analysis, 6, (6) pp. 563-567. ISSN 1942-7603 (2013) [Refereed Article] DOI: 10.1002/dta.1575 [eCite] [Details] Citations: Scopus - 15Web of Science - 15 Co-authors: Yee KC; Premilovac D; Rattigan S Tweet
2013	Jin F, Narkowicz C, Jacobson GA, 'Protoanemonin content variation between Clematis spp.: Leaf, Stem and Root', Natural Product Communications, 8, (2) pp. 211-212. ISSN 1934-578X (2013) [Refereed Article] PMID: 23513731 [eCite] [Details] Citations: Scopus - 2Web of Science - 1 Co-authors: Narkowicz C Tweet
2013	Pirie A, Parsons D, Renggli J, Narkowicz C, Jacobson GA, et al., 'Modulation of flavonoid and tannin production of Carpobrotus rossii by environmental conditions', Environmental and Experimental Botany, 87 pp. 19-31. ISSN 0098-8472 (2013) [Refereed Article] DOI: 10.1016/j.envexpbot.2012.10.001 [eCite] [Details] Citations: Scopus - 19Web of Science - 17 Co-authors: Pirie A; Parsons D; Narkowicz C; Shabala S Tweet
2012	Cui H, Hung AC, Freeman C, Narkowicz C, Jacobson GA, et al., 'Size and sulfation are critical for the effect of heparin on APP processing and A beta production', Journal of Neurochemistry, 123, (3) pp. 447-457. ISSN 0022-3042 (2012) [Refereed Article] DOI: 10.1111/j.1471-4159.2012.07929.x [eCite] [Details] Citations: Scopus - 12Web of Science - 11 Co-authors: Cui H; Hung AC; Narkowicz C; Small DH Tweet
2012	Jacobson GA, Ives SJ, Narkowicz C, Jones G, 'Plasma glutathione peroxidase (GSH-Px) concentration is elevated in rheumatoid arthritis: a case-control study', Clinical Rheumatology, 31, (11) pp. 1543-1547. ISSN 0770-3198 (2012) [Refereed Article] DOI: 10.1007/s10067-012-2046-9 [eCite] [Details] Citations: Scopus - 16Web of Science - 13 Co-authors: Ives SJ; Narkowicz C; Jones G Tweet
2011	Cui H, Hung AC, Klaver DW, Suzuki T, Freeman C, et al., 'Effects of heparin and enoxaparin on APP processing and Aβ production in primary cortical neurons from Tg2576 mice', PLoS One, 6, (7) Article e23007. ISSN 1932-6203 (2011) [Refereed Article] DOI: 10.1371/journal.pone.0023007 [eCite] [Details] Citations: Scopus - 25Web of Science - 15 Co-authors: Cui H; Hung AC; Klaver DW; Narkowicz C; Small DH Tweet
2011	Geraghty DP, Ahuja KDK, Pittaway J, Shing C, Jacobson GA, et al., 'In vitro antioxidant, antiplatelet and anti-inflammatory activity of Carpobrotus rossii (pigface) extract', Journal of Ethnopharmacology, 134, (1) pp. 97-103. ISSN 0378-8741 (2011) [Refereed Article] DOI: 10.1016/j.jep.2010.11.060 [eCite] [Details] Citations: Scopus - 21Web of Science - 22 Co-authors: Geraghty DP; Ahuja KDK; Pittaway J; Shing C; Jager N; Jurkovic S; Narkowicz C; Saunders CI; Ball M; Pinkard A; Adams MJ Tweet
2011	Pirie A, Shabala S, Parsons D, Narkowicz C, Jacobson G, et al., 'Ecophysiology of Carpobrotus rossii in Tasmania: Linking plant's antioxidant activity with a natural habitat', Ecological Questions , 14 pp. 91-93. ISSN 1644-7298 (2011) [Refereed Article] [eCite] [Details] Co-authors: Pirie A; Shabala S; Parsons D; Narkowicz C Tweet
2011	Yee KC, Jacobson GA, Wood-Baker R, Walters EH, 'Albuterol enantiomer levels, lung function and QTc interval in patients with acute severe asthma and COPD in the emergency department', International Journal of Emergency Medicine (Online) , 4, (1) Article 30. ISSN 1865-1380 (2011) [Refereed Article] DOI: 10.1186/1865-1380-4-30 [eCite] [Details] Citations: Scopus - 5 Co-authors: Yee KC; Wood-Baker R; Walters EH Tweet
2011	Yee KC, Lowe E, Jacobson GA, 'Determination of Albuterol Enantiomers in Animal Tissue Matrices by LC-MS/MS: Application in Therapeutic Myoanabolic Studies', Chromatographia, 74, (3-4) pp. 355-358. ISSN 0009-5893 (2011) [Refereed Article] DOI: 10.1007/s10337-011-2061-z [eCite] [Details] Citations: Scopus - 7Web of Science - 6 Co-authors: Yee KC; Lowe E Tweet
2010	Blair C, Walls J, Davies NW, Jacobson GA, 'Volatile organic compounds in runners near a roadway: increased blood levels after short-duration exercise', British Journal of Sports Medicine, 44, (10) pp. 731-735. ISSN 0306-3674 (2010) [Refereed Article] DOI: 10.1136/bjsm.2008.051888 [eCite] [Details] Citations: Scopus - 4Web of Science - 3 Co-authors: Blair C; Walls J; Davies NW Tweet
2010	Thomas J, Narkowicz CK, Jacobson GA, Davies NW, 'An examination of the essential oils of Tasmanian Kunzea ambigua, other Kunzea spp. and commercial kunzea oil', Journal of Essential Oil Research, 22, (5) pp. 381-385. ISSN 1041-2905 (2010) [Refereed Article] DOI: 10.1080/10412905.2010.9700351 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Thomas J; Narkowicz CK; Davies NW Tweet
2010	Thomas Jackson, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, et al., 'Toenail onychomycosis: an important global disease burden', Journal of Clinical Pharmacy and Therapeutics, 35, (5) pp. 497-519. ISSN 0269-4727 (2010) [Refereed Article] DOI: 10.1111/j.1365-2710.2009.01107.x [eCite] [Details] Citations: Scopus - 208Web of Science - 173 Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM Tweet
2009	Patel R, Narkowicz CK, Jacobson GA, 'Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin', Journal of Pharmaceutical Science, 98, (5) pp. 1700 - 1711. ISSN 0022-3549 (2009) [Refereed Article] DOI: 10.1002/jps.21556 [eCite] [Details] Citations: Scopus - 16Web of Science - 14 Co-authors: Patel R; Narkowicz CK Tweet
2009	Patel R, Narkowicz CK, Jacobson GA, 'Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution', Journal of Pharmaceutical Science, 98, (3) pp. 1118 - 1128. ISSN 0022-3549 (2009) [Refereed Article] DOI: 10.1002/jps.21483 [eCite] [Details] Citations: Scopus - 12Web of Science - 12 Co-authors: Patel R; Narkowicz CK Tweet
2009	Patel R, Narkowicz CK, Jacobson GA, 'Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins ', Analytical Biochemistry, 387, (1) pp. 113-121. ISSN 0003-2697 (2009) [Refereed Article] DOI: 10.1016/j.ab.2009.01.007 [eCite] [Details] Citations: Scopus - 35Web of Science - 36 Co-authors: Patel R; Narkowicz CK Tweet
2009	Thomas J, Narkowicz C, Peterson GM, Jacobson GA, Narayana A, 'Randomised controlled trial of the treatment of pastern dermatitis with a formulation containing kunzea oil', Veterinary Record, 164, (20) pp. 619-623. ISSN 0042-4900 (2009) [Refereed Article] DOI: 10.1136/vr.164.20.619 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Thomas J; Narkowicz C; Peterson GM; Narayana A Tweet
2009	Thomas Jackson, Webb CE, Narkowicz CK, Jacobson GA, Peterson GM, et al., 'Evaluation of repellent properties of volatile extracts from the Australian native plant Kunzea ambigua against Aedes aegypti (Diptera: Culcidae)', Journal of Medical Entomology, 46, (6) pp. 1387-1391. ISSN 0022-2585 (2009) [Refereed Article] DOI: 10.1603/033.046.0619 [eCite] [Details] Citations: Scopus - 13Web of Science - 14 Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM; Davies NW Tweet
2008	Patel R, Narkowicz CK, Hutchinson J, Hilder EF, Jacobson GA, 'A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins', Journal of Pharmaceutical and Biomedical Analysis, 46, (1) pp. 30-35. ISSN 0731-7085 (2008) [Refereed Article] DOI: 10.1016/j.jpba.2007.10.009 [eCite] [Details] Citations: Scopus - 63Web of Science - 54 Co-authors: Patel R; Narkowicz CK; Hutchinson J; Hilder EF Tweet
2008	Patel R, Narkowicz CK, Jacobson GA, 'In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose', Clinical Therapeutics, 30, (10) pp. 1880-1885. ISSN 0149-2918 (2008) [Refereed Article] DOI: 10.1016/j.clinthera.2008.10.014 [eCite] [Details] Citations: Scopus - 6Web of Science - 7 Co-authors: Patel R; Narkowicz CK Tweet
2007	Jacobson GA, Narkowicz CK, Lord RJ, Howard B-J, Chung S, 'Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus', Diseases of the Esophagus, 20, (3) pp. 265-268. ISSN 1120-8694 (2007) [Refereed Article] DOI: 10.1111/j.1442-2050.2007.00684.x [eCite] [Details] Citations: Scopus - 5Web of Science - 4 Co-authors: Narkowicz CK; Lord RJ Tweet
2007	Jacobson GA, Tong YC, Townsend AT, Featherstone AM, Ball MJ, et al., 'Selenium status in Southern Tasmania', European Journal of Clinical Nutrition, 61, (9) pp. 1057-1063. ISSN 0954-3007 (2007) [Refereed Article] DOI: 10.1038/sj.ejcn.1602628 [eCite] [Details] Citations: Scopus - 8Web of Science - 7 Co-authors: Tong YC; Townsend AT; Featherstone AM; Ball MJ; Robertson IK; Peterson GM Tweet
2007	Jacobson GA, Yee K, Ng CH, 'Elevated plasma glutathione peroxidase concentration in acute severe asthma: Comparison with plasma glutathione peroxidase activity, selenium and malondialdehyde', Scandinavian Journal of Clinical and Laboratory Investigation, 67, (4) pp. 423-430. ISSN 0036-5513 (2007) [Refereed Article] DOI: 10.1080/00365510601153353 [eCite] [Details] Citations: Scopus - 20Web of Science - 18 Co-authors: Yee K Tweet
2006	Cunningham CP, Brown JM, Jacobson GA, Brandon MR, Martinod SR, 'Evaluation of a covered-rod silicone implant containing ivermectin for long-term prevention of heartworm infection in dogs', American Journal of Veterinary Research, 67, (9) pp. 1564-1569. ISSN 0002-9645 (2006) [Refereed Article] DOI: 10.2460/ajvr.67.9.1564 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Tweet
2006	Jacobson GA, Martinod S, Cunningham CP, 'Determination of ceftiofur in bovine plasma by HPLC-DAD', Journal of Pharmaceutical and Biomedical Analysis, 40, (5) pp. 1249-1252. ISSN 0731-7085 (2006) [Refereed Article] DOI: 10.1016/j.jpba.2005.09.010 [eCite] [Details] Citations: Scopus - 28Web of Science - 26 Tweet
2006	Jacobson GA, Narkowicz CK, Tong YC, Peterson GM, 'Plasma glutathione peroxidase by ELISA and relationship to selenium level', Clinica Chimica Acta, 369, (1) pp. 100-103. ISSN 0009-8981 (2006) [Refereed Article] DOI: 10.1016/j.cca.2006.01.007 [eCite] [Details] Citations: Scopus - 27Web of Science - 22 Co-authors: Narkowicz CK; Tong YC; Peterson GM Tweet
2005	Jacobson GA, Featherstone AM, Townsend AT, Lord RJ, Peterson GM, 'Selenoprotein P analysis in human plasma - A discrepancy between HPLC fractionation of human plasma with heparin-affinity chromatography and SDS-PAGE with immunoblot analysis', Biological Trace Element Research, 107, (3) pp. 213-220. ISSN 0163-4984 (2005) [Refereed Article] DOI: 10.1385/BTER:107:3:213 [eCite] [Details] Citations: Scopus - 7Web of Science - 6 Co-authors: Featherstone AM; Townsend AT; Lord RJ; Peterson GM Tweet
2005	Pourmokhtar M, Jacobson GA, 'Enhanced stability of sulfamethoxazole and trimethoprim against oxidation using hydroxypropyl-B-cyclodextrin', Pharmazie, 60, (11) pp. 837-839. ISSN 0031-7144 (2005) [Refereed Article] PMID: 16320945 [eCite] [Details] Citations: Scopus - 15Web of Science - 12 Co-authors: Pourmokhtar M Tweet
2004	Featherstone AM, Townsend AT, Jacobson GA, Peterson GM, 'Comparison of methods for the determination of total selenium in plasma by magnetic sector inductively coupled plasma mass spectrometry', Analytica Chimica Acta, 512, (2) pp. 319-327. ISSN 0003-2670 (2004) [Refereed Article] DOI: 10.1016/j.aca.2004.02.058 [eCite] [Details] Citations: Scopus - 33Web of Science - 31 Co-authors: Featherstone AM; Townsend AT; Peterson GM Tweet
2004	Townsend AT, Featherstone AM, Chery CC, Vanhaecke F, Kirby J, et al., 'Increased selenium concentrations in seronorm trace elements serum', Clinical Chemistry, 50, (8) pp. 1481. ISSN 0009-9147 (2004) [Letter or Note in Journal] [eCite] [Details] Co-authors: Townsend AT; Featherstone AM; Peterson GM
2003	Jacobson GA, Chong FV, Davies NW, 'LC-MS method for the determination of albuterol enantiomers in human plasma using manual solid-phase extraction and a non-deuterated internal standard', Journal of Pharmaceutical and Biomedical Analysis, 31, (6) pp. 1237-1243. ISSN 0731-7085 (2003) [Refereed Article] DOI: 10.1016/S0731-7085(02)00734-3 [eCite] [Details] Citations: Scopus - 30Web of Science - 29 Co-authors: Davies NW Tweet
2003	Jacobson GA, Chong FV, Wood-Baker R, '(R,S)-Salbutamol plasma concentrations in severe asthma', Journal of Clinical Pharmacy and Therapeutics, 28, (3) pp. 235-238. ISSN 0269-4727 (2003) [Refereed Article] DOI: 10.1046/j.1365-2710.2003.00483.x [eCite] [Details] Citations: Scopus - 9Web of Science - 7 Co-authors: Wood-Baker R Tweet
2003	Jacobson GA, McLean SR, 'Biological monitoring of low level occupational xylene exposure and the role of recent exposure', Annals of Occupational Hygiene, 47, (4) pp. 331-336. ISSN 0003-4878 (2003) [Refereed Article] DOI: 10.1093/annhyg/meg045 [eCite] [Details] Citations: Scopus - 22Web of Science - 18 Co-authors: McLean SR Tweet
1998	Jacobson GA, Blizzard CL, Dwyer T, 'Bicycle injuries: road trauma is not the only concern', Australian and New Zealand Journal of Public Health, 22, (4) pp. 451-455. ISSN 1326-0200 (1998) [Refereed Article] DOI: 10.1111/j.1467-842X.1998.tb01413.x [eCite] [Details] Citations: Scopus - 35Web of Science - 35 Co-authors: Blizzard CL; Dwyer T Tweet
1997	Jacobson GA, Peterson GM, McLean SR, 'Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy', Journal of Clinical Pharmacy and Therapeutics, 22, (2) pp. 119-126. ISSN 0269-4727 (1997) [Refereed Article] DOI: 10.1111/j.1365-2710.1997.tb00005.x [eCite] [Details] Citations: Scopus - 12Web of Science - 12 Co-authors: Peterson GM; McLean SR Tweet
1996	Jacobson GA, Peterson GM, 'Prescribing trends for anti-asthma drugs in Tasmania following the National Asthma Campaign', Journal of Clinical Pharmacy and Therapeutics, 21, (5) pp. 317-324. ISSN 1365-2710 (1996) [Refereed Article] DOI: 10.1111/j.1365-2710.1996.tb00025.x [eCite] [Details] Citations: Scopus - 7Web of Science - 4 Co-authors: Peterson GM Tweet
1995	Jacobson GA, Peterson GM, 'Stability of ipratropium bromide and salbutamol nebuliser admixtures', International Journal of Pharmacy Practice, 3, (3) pp. 169-173. ISSN 2042-7174 (1995) [Refereed Article] DOI: 10.1111/j.2042-7174.1995.tb00812.x [eCite] [Details] Citations: Scopus - 8 Co-authors: Peterson GM Tweet
1994	Jacobson GA, Peterson GM, 'High-performance liquid chromatographic assay for the simultaneous determination of ipratropium bromide, fenoterol, salbutamol and terbutaline in nebulizer solution', Journal of Pharmaceutical and Biomedical Analysis, 12, (6) pp. 825-32. ISSN 0731-7085 (1994) [Refereed Article] DOI: 10.1016/0731-7085(94)E0006-M [eCite] [Details] Citations: Scopus - 50Web of Science - 36 Co-authors: Peterson GM Tweet
1992	Jacobson GA, Friesen WT, Peterson GM, Rumble RH, Polack AE, 'Psychoactive drug prescribing in the Tasmanian community', Medical Journal of Australia, 157, (1) pp. 20-4. ISSN 0025-729X (1992) [Refereed Article] DOI: 10.5694/j.1326-5377.1992.tb121601.x [eCite] [Details] Citations: Scopus - 14Web of Science - 12 Co-authors: Friesen WT; Peterson GM; Rumble RH; Polack AE Tweet

Conference Publication

(39 outputs)

Year	Citation	Altmetrics
2018	Ferguson SG, Narkowicz CK, Jacobson G, 'Urine or blood: does it matter how you calculate the nicotine metabolism ratio?', SRNT - E 2018, 6-8 September 2018, Munich (2018) [Conference Extract] [eCite] [Details] Co-authors: Ferguson SG; Narkowicz CK
2016	De Paoli AG, Wilson RR, Vervaart P, Dargaville PA, Jacobson GA, 'Identifying novel markers of late onset neonatal sepsis using proteomic analysis', Proceedings of the 20th Annual Congress of the Perinatal Society of Australia and New Zealand, May 22nd-25th, 2016, Townsville, Australia (2016) [Conference Extract] [eCite] [Details] Co-authors: De Paoli AG; Wilson RR; Dargaville PA
2016	Hu Donghua, Russell RD, Sharman JE, Rattigan S, Jacobson GA, et al., 'Effect of blueberry tea on improving metabolic and vascular function in people with and without type 2 diabetes - A Pilot Study', Australian Diabetes Society and Australian Diabetes Educators Association Annual Scientific Meeting 2016, 24-26 August, 2016, Gold Coast, Australia (2016) [Conference Extract] [eCite] [Details] Co-authors: Russell RD; Sharman JE; Rattigan S; Al-Aubaidy HAM; Richards SM; Keske MAV
2016	Raidal S, Jacobson GA, Robson K, Narkowicz CK, Nichols DS, et al., 'Enantioselective bronchopulmonary pharmacokinetics of salbutamol in horses', 2016 ACVIM Forum, 8-11 June, 2016, Denver, Colorado (2016) [Conference Extract] [eCite] [Details] Co-authors: Narkowicz CK; Nichols DS; Walters EH
2016	Shafuddin E, Cooray M, Tuffery C, Hopping S, Sullivan G, et al., 'High-dose beta2-agonist treatment is associated with cardiac dysfunction in chronic obstructive pulmonary disease', Respirology, pp. 24. ISSN 1323-7799 (2016) [Conference Extract] [eCite] [Details]
2015	Hoyle D, Jacobson GA, Cui H, Rodemann T, 'Investigation of amyloid plaques and enoxaparin brain penetration using Raman and infrared spectroscopy', 2015 Joint APSA-ASCEPT Annual Conference, 29 November - 2 December, 2015, Hobart, Tasmania (2015) [Conference Extract] [eCite] [Details] Co-authors: Hoyle D; Cui H; Rodemann T
2015	Jacobson GA, 'Investigation of salbutamol enantiomer deposition in epithelial lining fluid in horses', APSA-ASCEPT Joint Scientific Meeting 2015, 9 October, 2015, Hobart, Tasmania (2015) [Conference Extract] [eCite] [Details]
2014	Pirie AD, Ahuja KDK, Jacobson GA, Geraghty DP, Narkowicz CK, et al., 'Glucose tolerance is improved by supplementation with carpobrotus rossii flavanoids in insulin resistant mice', Thirty-Eighth Annual Scientific Meeting of The Nutrition Society of Australia, 26 - 28 November, 2014, Hobart, Tasmania (2014) [Conference Extract] [eCite] [Details] Co-authors: Pirie AD; Ahuja KDK; Geraghty DP; Narkowicz CK; Keske MA
2012	Cui H, Hung AC, Freeman C, Narkowicz CK, Jacobson GA, et al., 'Effects of glycosaminoglycans on the level of β- and α-secretase and APP processing in Tg2576 primary cortical cells', APSN 2012, 29 September - 2 October, 2012, Kobe, Japan (2012) [Conference Extract] [eCite] [Details] Co-authors: Cui H; Hung AC; Narkowicz CK; Small DH
2012	Cui H, Hung AC, Narkowicz CK, Jacobson GA, Small DH, 'Effects of glycosaminoglycans on the level of β- and α-secretase and APP processing in Tg2576 primary cortical cells', Australian Neuroscience Society Annual Meeting, 29 January - 1 February, 2012, Gold Coast, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Cui H; Hung AC; Narkowicz CK; Small DH
2011	Cui H, Hung AC, Klaver D, Narkowicz CK, Jacobson GA, et al., 'Effects of heparin and enoxaparin on APP processing and Aβ production in primary cortical neurons from Tg2576 mice', Australian Neuroscience Society 31st Annual Meeting, 31 January - 3 February, 2011, Auckland, New Zealand (2011) [Conference Extract] [eCite] [Details] Co-authors: Cui H; Hung AC; Klaver D; Narkowicz CK; Small DH
2011	Jin FM, Narkowicz CK, Bradbury RS, Bettiol SS, Mortia Y, et al., 'Ranunculin the antibacterial constituent in Clematis aristata, and its mode of action', Proceedings of APSA, 11 - 14 Dec, Adelaide (2011) [Conference Extract] [eCite] [Details] Co-authors: Jin FM; Narkowicz CK; Bradbury RS; Bettiol SS
2010	Geraghty DP, Jacobson GA, Narkowicz CK, Shing C, Pirie A, 'Effect of chronic Carpobrotus rossii (pigface) ingestion on systolic blood pressure, body weight, blood lipids, haematological profile and in vitro vascular function in adult male rats', Proceedings of ASCEPT, Dec 2010, Melbourne, pp. P36. (2010) [Conference Extract] [eCite] [Details] Co-authors: Geraghty DP; Narkowicz CK; Shing C; Pirie A
2009	Adams MJ, Pinkard A, Geraghty DP, Jacobson GA, Narkowicz CK, et al., 'Antiplatelet activity of Carpobrotus rossii (pigface) extract', Proceedings of ASCEPT, November, 2009, Sydney). O79., Sydney, pp. O79. (2009) [Conference Extract] [eCite] [Details] Co-authors: Adams MJ; Pinkard A; Geraghty DP; Narkowicz CK; Ball MJ; Ahuja KDK
2009	Geraghty DP, Jurkovic S, Vennavaram RR, Jager NGL, Jacobson GA, et al., 'Antioxidant activity of Carpobrotus rossii (pigface) extract', Proceedings of ASCEPT, November, 2009, Sydney). O79., Sydney, pp. O79. (2009) [Conference Extract] [eCite] [Details] Co-authors: Geraghty DP; Jurkovic S; Jager NGL; Narkowicz CK; Ball MJ; Ahuja KDK
2009	Jin FM, Narkowicz CK, Jacobson GA, 'Studies on the potential anticancer compounds of Tasmanian Clematis species', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre, Hobart, Tasmania, pp. 124. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Jin FM; Narkowicz CK
2009	Liu T, Narkowicz CK, Jacobson GA, Hu X, 'Studies of chemical modification and formation of colon targeted microparticulates of Pachyman', Australasian Pharmaceutical Science Association Annual Conference Aus-CRS Symposium Program and Abstract book, 9-11 December 2009, Wrest Point Convention Centre, Hobart Tasmania, pp. 184. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Narkowicz CK
2009	Patel RP, Narkowicz CK, Jacobson GA, 'A low-volume microtitre plate assay for determination of the AFXa activity of enoxaparin', Australasian Pharmaceutical Science Association Annual Conference Aus-CRS Symposium Program and Abstract book, 9-11 December 2009, Wrest Point Convention Centre, Hobart Tasmania, pp. 140. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Patel RP; Narkowicz CK
2009	Thomas Jackson, Narkowicz CK, Jacobson GA, Davies NW, 'An examination of the essential oils of Tasmanian Kunzea ambigua, other Kunzea spp. and commercial kunzea oil', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre, Hobart, Tasmania, pp. 118. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Thomas Jackson; Narkowicz CK; Davies NW
2009	Thomas Jackson, Narkowicz CK, Jacobson GA, Peterson GM, Basson S, 'An evaluation of the clinical efficacy of kunzea oil formulations in the therapeuticmanagement of psoriasis in adults', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre,Hobart, Tasmania , pp. 117. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM
2009	Thomas Jackson, Narkowicz CK, Jacobson GA, Peterson GM, Burnet H, et al., 'A randomised trial of kunzea oil in comparison with amorolfine nail lacquer for the treatment of toenail onychomycosis', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre, pp. 71. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM
2009	Yee K, Jacobson GA, Wood-Baker R, Walters EH, 'Serum salbutamol enantiomer levels and extra pulmonary effects during disease exacerbation of COPD', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre, pp. 68. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Yee K; Wood-Baker R; Walters EH
2009	Yee K, Jacobson GA, Wood-Baker R, Walters EH, 'Genetic variations at activator protein-1 among patients with steroid-insensitive asthma', Out of the Wilderness - 2009 APSA Annual Conference program and abstracts booklet, 9-11 December 2009, Wrest Point Convention Centre, Hobart, Tasmania, pp. 128. ISBN 978-0-646-52257-9 (2009) [Conference Extract] [eCite] [Details] Co-authors: Yee K; Wood-Baker R; Walters EH
2008	Jacobson GA, 'Barrett's oesophagus: pilot application of MudPIT proteomics to oesophageal tissue after proton pump inhibitor therapy', Teams for tomorrow, 6-9 December 2008, Canberra, ACT, pp. 108. ISBN 1111111111 (2008) [Conference Extract] [eCite] [Details]
2008	Jin FM, Narkowicz CK, Jacobson GA, 'The screening of chemical constituents, antitumour and antimicrobial activities of Tasmanian clematis species', Teams for tomorrow, 6-9 December 2008, Canberra, ACT, pp. 108. (2008) [Conference Extract] [eCite] [Details] Co-authors: Jin FM; Narkowicz CK
2008	Narkowicz CK, Philip P, Jacobson GA, 'The chemistry and pharmaceutical potential of Callitris spp. from Tasmania', Teams for tomorrow, 6-9 December 2008, Canberra, ACT, pp. 108. (2008) [Conference Extract] [eCite] [Details] Co-authors: Narkowicz CK
2008	Narkowicz CK, Tieojaroenporn N, Jacobson GA, 'Saliva treatment of Dodoneae viscosa increases its antibacterial activity', Teams for tomorrow, 6-9 December 2008, Canberra, ACT, pp. 108. (2008) [Conference Extract] [eCite] [Details] Co-authors: Narkowicz CK
2007	Jacobson GA, Ives S, Narkowicz CK, Jones G, 'Elevated plasma glutathione peroxidase concentration in rheumatoid arthritis', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Ives S; Narkowicz CK; Jones G
2007	Jacobson GA, Yee K, Winburg M, 'Enantioselective distribution of (R/S)-salbutamol in skeletal muscle in a spinal muscular atrophy mouse model', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Yee K
2007	Patel R, Narkowicz CK, Jacobson GA, 'The effect of heating on the chemistry and biological activity of enoxaparin', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Patel R; Narkowicz CK
2007	Patel R, Narkowicz CK, Jacobson GA, 'The effects of freezing and thawing on the AFXa activity of enoxaparin solution', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Patel R; Narkowicz CK
2007	Patel R, Narkowicz CK, Jacobson GA, 'Separation and characterisation of different low-molecular-weight heparins by reversed-phase ion-interaction high-performance liquid chromatography', Proceedings of the APSA Annual Conference, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Extract] [eCite] [Details] Co-authors: Patel R; Narkowicz CK
2007	Thomas J, Narkowicz CK, Jacobson GA, Peterson GM, Davies NW, 'Characterisation and evaluation of the in vitro antimicrobial activity of Kunzea ambigua essential oil', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Thomas J; Narkowicz CK; Peterson GM; Davies NW
2007	Thomas Jackson, Narkowicz CK, Peterson GM, Jacobson GA, Narayana AK, 'Treatment of pastern dermatitis with a formulation containing kunzea oil' a randomised controlled trail', Annual Conference of Australasian Pharmaceutical Science Association Program and Abstract Book, 8-11 December 2007, Manly, NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Extract] [eCite] [Details] Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM; Narayana AK
2007	Vennavaram RR, Narkowicz CK, Jacobson GA, 'Chemical content and antioxidant activity of Carpobrotus rossii, C. edulis and C. aequilaterus', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Narkowicz CK
2007	Webb C, Thomas Jackson, Narkowicz CK, Jacobson GA, Peterson GM, et al., 'Is the essential oil from the Australian native plant Kunzea ambigua repellent to mosquitoes?', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Thomas Jackson; Narkowicz CK; Peterson GM; Davies NW
2007	Yee K, Jacobson GA, Wood-Baker R, Walters EH, 'Montelukast pharmacogenetics in a clinical setting as an adjunct therapy among patients using corticosteroids', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Yee K; Wood-Baker R; Walters EH
2007	Yee K, Jacobson GA, Wood-Baker R, Walters EH, 'SULT1A3 Single Nucleotide Polymorphisms (SNPs) and their effect on Salbutamol Enantiomer Pharmacokinetics', Australian Pharmaceutical Science Association, 8-11 December 2007, Manly NSW, pp. 205. ISBN 978-0-646-48458-7 (2007) [Conference Edited] [eCite] [Details] Co-authors: Yee K; Wood-Baker R; Walters EH
2004	Townsend AT, Featherstone AM, Jacobson GA, Peterson GM, 'The Determination of Selenium in Human Plasma by Magnetic Sector ICP-MS', Abstract, 4-8 July 2004, Gold Coast, Queensland, Australia, pp. 209. (2004) [Conference Extract] [eCite] [Details] Co-authors: Townsend AT; Featherstone AM; Peterson GM

Patent

(1 outputs)

Year	Citation	Altmetrics
2003	Peterson GM, Jacobson GA, 'A syringe guard' (2003) [Patent] [eCite] [Details] Co-authors: Peterson GM

Year

Citation

Altmetrics

2003

Peterson GM, Jacobson GA, 'A syringe guard' (2003) [Patent]

[eCite] [Details]

Co-authors: Peterson GM

Thesis

(1 outputs)

Year	Citation	Altmetrics
1996	Jacobson GA, 'Aspects of the Pharmacotherapay of Airways Disease' (1996) [PhD] [eCite] [Details]

Other Public Output

(21 outputs)

Year	Citation	Altmetrics
2015	Jacobson GA, 'ABC Australia Wide Story on beta2-agonist doping control', Australia Wide November 21, ABC News, Online (2015) [Media Interview] [eCite] [Details]
2015	Jacobson GA, 'Tasmanian researchers scrutinise athletes' use of asthma treatment as performance enhancer', ABC News, Online (2015) [Media Interview] [eCite] [Details]
2014	Jacobson GA, 'Guest Blog: WADA turns to Tasmania in anti-doping efforts', SBS Cycling Central (2014) [Media Interview] [eCite] [Details]
2014	Jacobson GA, 'World Anti-Doping Agency's drug war comes to Tasmania', The Mercury, Online, August 12, 2014 (2014) [Newspaper Article] [eCite] [Details]
1998	Jacobson GA, 'TISPP Risk', RISK Bulletin, Tasmanian Injury Surveillance & Prevention Project, Tasmania, 44, June (1998) [Internal Newsletter] [eCite] [Details]
1997	Jacobson GA, 'Bike injuries', Bike injuries, Examiner, Tasmania, 15 Jan (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'T.I.S.P.P. RISK', RISK Bulletin, The Tasmanian Injury Surveillance and Prevention Program/Department of Community and Health Services, Tasmania, 42, May (1997) [Internal Newsletter] [eCite] [Details]
1997	Jacobson GA, 'T.I.S.P.P. RISK', RISK Bulletin, The Tasmanian Injury Surveillance and Prevention Program/Department of Community and Health Services, Tasmania, 43, October (1997) [Internal Newsletter] [eCite] [Details]
1997	Jacobson GA, 'Eye injuries', Eye injuries, Mercury, Tasmania, 30 May (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'Eye injuries', Eye injuries, Advocate, Tasmania, 4 Jun (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'Dangers of roller blading', Dangers of roller blading, Sunday Tasmanian, Tasmania, 13 Jul (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'Bike safety leaflet for young riders', Bike safety leaflet for young riders, The Star, Tasmania, 30 Oct (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'Netball most dangerous sport for females', The Mercury, Tasmania, 20/11/97 (1997) [Newspaper Article] [eCite] [Details]
1997	Jacobson GA, 'TISPP - eye injuries', TTT-FM News, Tasmania, 30/5/97 (1997) [Media Interview] [eCite] [Details]
1997	Jacobson GA, 'Bike Injuries', WIN TV News, Tasmania, 7/6/97 (1997) [Media Interview] [eCite] [Details]
1996	Jacobson GA, 'Most bike injuries 'off public roads'', The Examiner, Tasmania, January 15 (1996) [Newspaper Article] [eCite] [Details]
1996	Jacobson GA, 'Roads and guns most lethal risks', The Mercury, Tasmania, June 25 (1996) [Newspaper Article] [eCite] [Details]
1996	Jacobson GA, 'Tasmanian injury and prevention project', ABC Radio 7NT, Tasmania, 25 June (1996) [Media Interview] [eCite] [Details]
1996	Jacobson GA, 'Bike Injuries', Risk Bulletin, Tasmania, 40, Sept (1996) [Internal Newsletter] [eCite] [Details]
1996	Jacobson GA, 'Fatal Injuries in Tasmania from 1991 to 1994', Risk Bulletin, Tasmania, 39, June (1996) [Internal Newsletter] [eCite] [Details]
1996	Jacobson GA, 'Childhood Injuries', Risk Bulletin, Tasmania, 41, Dec (1996) [Internal Newsletter] [eCite] [Details]

Grants & Funding

Dr Jacobson has been Chief Investigator on over 20 competitively funded grants securing over $1.3m of research funding during his career including ARC-LIEF and NHMRC, in addition to over $100k of industry funded research. Dr Jacobson has also been an associate investigator in the $4m NHMRC Centre for Research Excellence 'Breathe Well' related to his enantioselective beta2-agonist expertise. Dr Jacobson is internationally recognised for his work related to enantioselective beta2-agonist bioanalytical applications in the area of sports doping and has recently been the recipient of two international competitively funded World Anti-Doping Agency (WADA) research grants.

Funding Summary

Number of grants

Total funding

$2,587,229

Projects

Development of a non-invasive blood sampling technique to assess paracetamol toxicity severity and response to treatment (2022)$9,812

Description: This project involves development of a simple, minimally invasive Volumetric Absorptive Microsampling (VAMS) analysis of paracetamol and alanine aminotransferase (ALT) levels to provide easier and safer management of patients with paracetamol toxicity due to overdose.
Funding: Royal Hobart Hospital Research Foundation ($9,812)
Scheme: Grant-Incubator
Administered By: University of Tasmania
Research Team: Veal FC; Patel RP; Jacobson GA; Nichols DS; Wanandy T; Handley S; Tran V
Year: 2022

Evaluation of urine thresholds for salmeterol (2021 - 2022)$239,159

Description: Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, while the introduction of urinary thresholds and decision limits for salbutamol and formoterol is an innovative way to avoid excessive use by athletes and to lessen the economic burdens associated with therapeutic use exemption (TUE) applications, no thresholds exist for salmeterol which results in many Anti-Doping Rule Violations (ADRVs) per year . This project focuses on developing thresholds for salmeterol where there is currently no urine threshold.
Funding: World Anti-Doping Agency ($239,159)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA
Period: 2021 - 2022

Pre-clinical toxicity assessment of test compounds (2019)$8,677

Description: This project will assess the short-term toxicity of 12 test compounds for Martha Jane Medical.
Funding: Martha Jane Medical ($8,677)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Guven N; Jacobson GA
Year: 2019

Factors affecting pharmacokinetics of inhaled salbutamol in athletes: Application of 4O-sulfate metabolite analysis to improve predictive value of AAFs (2019)$207,087

Funding: World Anti-Doping Agency ($207,087)
Scheme: Grant
Administered By: University of Copenhagen
Research Team: Hostrup M; Jacobson GA
Year: 2019

Omeprazole formulation pharmacokinetics and pharmacodynamics in horses (2018)$33,460

Description: Omeprazole is used for the treatment and prevention of equine gastric ulcers in horses, however, administration of veterinary gels and tablets can be problematic. This is a biopharmaceutics project which focuses on the pharmacokinetics of a novel granule formulation administered to horses to improve ease of dosing and impact on the animal. Blood levels of omeprazole will be analysed from pharmacokinetic time course studies and compared to existing omeprazole products. The pharmacodynamics effects have been measured by gastric pH and relationship with PK factors will be explored. The euqine veterinary phase of the study has been completed by collaborators at Charles Sturt University (Wagga).
Funding: Equestra Pty Ltd ($33,460)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2018

Isolation and synthesis of potential new therapeutic agents from Hemp (Cannabis sativa) and their biological evaluation (2018 - 2021)$105,000

Description: Cannabis and cannabis extracts have been reported to have beneficial applications to many indications including the management of seizures, pain, cancer and appetite amongst others. One problem has been the illicit nature of the material which results in lack of control of the dose and chemical profile of material which can be due to different plant varieties, growing conditions, extraction preparation and mode of delivery. This project aims to adopt a drug discovery approach to provide solid evidence for the effect of different cannabinoids by isolating the individual components for thorough evaluation of any therapeutical applications. In this way, clear dose dependant activity can be studied and protocols for the prescription of cannabinoids can be developed that are in-line with modern pharmaceutical procedures. This will also be the start point for the development of novel semi-synthetic cannabinoids that will allow us to develop structure activity relationships for different indications. This potentially extends the scope of the medicinal cannabis industry to be a raw material for the synthesis of active non-natural derivates similar to the semi-synthetic opiates.
Funding: Martha Jane Medical ($105,000)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Smith JA; Jacobson GA; Guven N; Bissember AC
Period: 2018 - 2021

Exosome proteomics to detect biomarkers of erythropoietin (EPO) use in athletes (2018)$186,727

Description: Erythropoietin (EPO) is a 30 kDa glycoprotein hormone that controls red blood cell production, and is typically used to treat anemia resulting from chronic kidney disease. EPO is mainly produced in the kidneys, with production stimulated by hypoxia, with this hypoxia usually determined by red blood cell levels in the circulation. EPO is secreted into the plasma and binds to targets in the bone marrow (a 72 kDa receptor) which increases the ability of the marrow to produce more erythrocytes, and hence oxygen carrying capacity. There are a rapidly growing number of erythropoietin stimulating agents (ESAs) prohibited under S2 of the WADA Prohibited List, including erythropoietin and darbepoetin-alfa, as well as a plethora of hypoxia-inducible factor stabilisers (HIFs), EPO mimetic peptides such as peginesatide, and new third generation ESAs entering the market such as continuous erythropoietin receptor activators (CERA) including methoxy polythyethylene glycol-epoetin beta (Micera). This diverse range of compounds and development of new third generation agents highlights the difficulty in detection of these agents, and supports the rationale for platform -omics technologies for the development of biomarkers for detection of ESAs. There is conclusive evidence that EPO and ESAs more generally are performance enhancing in endurance sport. Sports such as distance running, cycling and cross country skiing where performance is reliant on delivery of oxygen to the skeletal muscles. The performance enhancing effects of recombinant human EPO (rhEPO) administered at relatively modest doses can result in a 6-12% increase in maximum oxygen carrying capacity, and also increase the time to exhaustion by as much as 50% at a given oxygen carrying capacity.rhEPO doping detection is problematic for many reasons. Firstly, EPO is endogenous and discrimination between the body's natural EPO and increased EPO through doping with administration of rhEPO is difficult; endogenous EPO may also be raised through doping with a variety of ESAs as well as indirect methods using the ever expanding class of HIFs. Secondly, the effects are profound with significant performance gains in endurance sports even after a washout of the EPO doping agent in terms of weeks. The specific detection of ESAs is currently based on two different approaches, the direct detection of exogenous agents and indirect detection of specific biomarkers, which is particularly promising with newer -omics approaches. Indirect evidence of rhEPO use is based on analysis of blood parameters including hemoglobin hematocrit and is contained in the Athlete Biologic Passport (ABP) but is limited in ability to provide smoking gun conclusive evidence. Although WADA publishes criteria in an attempt to ensure harmonization between laboratories, alarmingly, a significant study demonstrated very poor agreement between two accredited laboratories which was worse during the maintenance and washout periods.The project will study the proteome of extracellular vesicles called exosomes, with the objective of identifying biomarkers of rhEPO use. The application of proteomics to exosomes isolated from blood is an exciting area research. By applying nanoflow LC-MS/MS proteomics approaches to exosomes, one of the greatest limitation of current blood proteomics for doping biomarkers is overcome - the avoidance of high abundance plasma proteins. The study will consist of a physiological intervention trial, with highly trained male athletes visiting the NEXS clinic (Copenhagen) two weeks (-2), and one week (-1) before baseline (0) where subjects will undergo treatment with microdosed rhEPO (20 IU/kg every second day for two weeks), and subsequent visits at +1, +2, +3 weeks following treatment. Blood and urine will both be collected for exosome proteomics at each visit, along with a standard set of relevant exercise physiology tests (VO2). Exosomes will be isolated using the Total Exosome Isolation kit (Invitr
Funding: World Anti-Doping Agency ($186,727)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Wilson RR; Hostrup M; Bangsbo J
Year: 2018

To investigate the use of the nutraceutical supplement Thompsons Super Bioflavonoid Complex to reduce blood glucose levels in patients with type 2 diabetes as an alternative to prescription based glip (2017)$15,088

Description: This study will investigate the potential of commercially available nutraceutical supplements (Thompson's Cholesterol Manager, 500 mg/tablet, two tablets/day) to reduce blood glucose levels in patients with type 2 diabetes mellitus (T2DM). The action of these supplements is thought to be similar to the dipeptidyl peptidase-4 (DPP-4) inhibitor group, also known as gliptins, which are second line anti-diabetic drugs after metformin and sulfonylureas. The gliptins block the action of DPP-4, an enzyme which inhibits a group of gastrointestinal hormones called incretins.
Funding: Tasmanian Community Fund ($15,088)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Burgess JR; Al-Aubaidy H
Year: 2017

Investigating enantioselectivity of terbutaline and the application to doping control (2017 - 2018)$126,133

Description: Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol, salmeterol, and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, while the introduction of urinary thresholds and decision limits for salbutamol and formoterol is an innovative way to avoid excessive use by athletes and to lessen the economic burdens associated with therapeutic use exemption (TUE) applications, no thresholds exist for salmeterol and terbutaline. Especially for terbutaline, a urine threshold is relevant, since high dose inhalation and oral ingestion of terbutaline may enhance sprint performance and muscle strength when used acutely and for a longer duration. This project focuses on two ongoing research areas of beta2-agonists; salmeterol where there is currently no urine threshold, and terbutaline, a short acting beta2-agonist widely used in Europe but currently prohibited, which accounts for 76% of adverse analytical findings (AAFs) of beta2-agonists in doping control.
Funding: World Anti-Doping Agency ($126,133)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Hostrup M; Nichols DS; Walters EH
Period: 2017 - 2018

Enantioselective pharmacokinetics of formoterol and application to doping control (2015 - 2016)$195,350

Description: The objectives of this project are to improve windows of detection of formoterol doping using enantioselective urine analyses.
Funding: World Anti-Doping Agency ($195,350)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Walters EH; Nichols DS
Period: 2015 - 2016

Chemika impurity characterisation - ICH guidelines (2014)$8,794

Description: This project will identify degradation products that arise during routine quality control assays as part of compliance with ICH guidelines. Degradation products will be identified using a three step process of UPLC with low resolution MS and fractionation and purity testing, followed by high resolution MS (orbitrap), with subsequent NMR.
Funding: Chemika Pty ltd ($8,794)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA; Davies NW; Wilson RK; Horne HJ; Smith JA
Year: 2014

Medication stability in the Pacific Islands (2014 - 2015)$16,364

Description: There are limited facilities in Pacific Island countries for pharmacovigilance and quality assurance services and most do not have any formal regulatory body (such as the Therapeutic Goods Administration in Australia) that approves medicines imported into the country. Quality is also confounded by cost and limited supply whereby drugs may need to be used beyond expiry date, as well as storage facilities and transport logistics in hot and humid environments; this can lead to medicines that may not be optimal when dispensed to patients. Even more concerning is the potential link between poor quality or ineffective medications and the emergence of resistance to antibiotics including anti-tuberculosis drugs. The project will undertake the chemical analysis of a range of common antibiotic drug batches at central storage facilities (including antibiotic tablets) using USP/BP testing with HPLC. These data will be used for research purposes; to assess the quality of medications in these nations building on previous research and provide data for the development of a drug storage and quality repository.
Funding: Dr Simon Quilty ($16,364)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Jacobson GA
Period: 2014 - 2015

Enantioselective salbutamol analysis in blood of COPD patients (2014)$4,637

Description: Coexisting heart failure in patients with chronic obstructive pulmonary disease (COPD) is common, but often overlooked. Biomarkers of heart failure, such as brain natriuretic peptide (BNP) have been shown to predict mortality in COPD patients, although the mechanism behind this remains unclear. This study explores the mechanism that links cardiac dysfunction and COPD by studying the trends of cardiac biomarker levels in COPD patients and the correlation with clinical and cardiac functional assessments, and survival. This is a prospective study of COPD patients presenting with acute exacerbations, with no symptoms or signs suggesting acute coronary syndrome or acute pulmonary oedema. The project aims to recruit these participants when they are hospitalised and follow them up for 12 months. Participants will be reassessed during convalescence from these exacerbations (30-days from hospitalisation). Data including clinical, laboratory and cardiac functional findings will be collected during episode of acute exacerbation and during convalescence. Cardiac biomarkers will be measured on presentation, at 12 hours, at 72 hours (or on discharge, whichever is earlier) and during convalescence. The project will then investigate the trends of cardiac biomarkers correlated with the changes in clinical and cardiac functional assessments. The trends of cardiac biomarkers in patients with hypercapnic respiratory failure receiving non-invasive ventilation (NIV) will also be studied. Research will assess whether high levels of cardiac biomarkers at exacerbations correlate with serum beta-agonist levels. This will elucidate if the changes in cardiac biomarkers during acute exacerbation of COPD are associated with deterioration in cardiac function and the nature of this change in cardiac function (right or left ventricle). Simultaneous measurement of cardiac biomarkers and serum beta-agonist levels will address one of the potential explanations for the link between COPD exacerbations and cardiac dysfunction. The findings of this study may influence the treatment of cardiac disease in COPD patients.
Funding: Waikato Hospital ($4,637)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2014

Enantioselective pharmacokinetics of salbutamol and application to doping control (2014 - 2015)$139,880

Description: We will apply our advanced analytical technique that can measure both R- and S-salbutamol in urine, to samples from patients treated with either oral or inhaled therapy over the course of a week. The project will validate the benefits, namely increased sensitivity and reduced false positives and false negatives, of measuring R- and S-salbutamol enantiomers. This will allow to better discriminate between oral and inhaled salbutamol.
Funding: World Anti-Doping Agency ($139,880)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Walters EH
Period: 2014 - 2015

Zebrafish: Pilot Applications in Muscle and Angiogenesis (2012)$5,000

Funding: University of Tasmania ($5,000)
Scheme: Grant-Research Enhancement (REGS)
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2012

Purchase of a new generation fast mapping Raman system (2011)$240,000

Description: The new fast imaging Raman system will be used to satisfy the research needs of a wide range of research projects within the chemical, health, pharmaceutical, material and earth sciences at UTAS. The facility is expected to substantially enhance the research outcomes of several internationally renowned researchers at UTAS.
Funding: Australian Research Council ($240,000)
Scheme: Grant-Linkage Infrastructure
Administered By: University of Tasmania
Research Team: Kamenetsky VS; Breadmore MC; Vickers JC; Jacobson GA; McGuinness DS
Year: 2011
Grant Reference: LE110100041

Development of a Simple and Effective Ion-chromatagraphic Analysis for the Separation and Identification of Non-anticoagulant fractions of Enoxaparin (2011)$6,950

Funding: University of Tasmania ($6,950)
Scheme: Grant-Cross Theme
Administered By: University of Tasmania
Research Team: Patel RP; Hutchinson J; Johns CA; Jacobson GA; Narkowicz CK; Peterson GM
Year: 2011

The Potential Role of Human Papilloma Virus in Short and Long Segment Barrett's Oesophagus and the Development of Dysplasia (2011 - 2012)$63,636

Funding: Clifford Craig Foundation ($63,636)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Rajendra S; Snow ET; Ball MJ; Robertson IK; Jacobson GA
Period: 2011 - 2012

Investigations of the Chemical and Physical Stability of Iron Polymaltose Intravenous Infusion (2011)$6,364

Funding: Royal Hobart Hospital Research Foundation ($6,364)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Wanandy ST; Patel RP; Randall C; Jacobson GA; Holmes SE; Hutchinson C; Johns CA
Year: 2011

Walter and Eliza Hall Fungal Screening Project (2010)$5,434

Funding: Walter and Eliza Hall Institute of Medical Research ($5,434)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Jacobson GA; Narkowicz CK
Year: 2010

Purchase of an ultra-performance liquid chromatograph-triple quadrupole mass spectrometer (2010)$200,000

Funding: Australian Research Council ($200,000)
Scheme: Grant-Linkage Infrastructure
Administered By: University of Tasmania
Research Team: Davies NW; Reid JB; Canty AJ; Potts BM; Tamplin ML; Mohammed CL; Ross JJ; O'Reilly-Wapstra JM; Jacobson GA; Wright SW
Year: 2010
Grant Reference: LE100100015

Identifying Novel Markers of Neonatal Sepsis (2010)$7,273

Funding: Royal Hobart Hospital Research Foundation ($7,273)
Scheme: Grant-Starter
Administered By: Royal Hobart Hospital Research Foundation
Research Team: De Paoli AG; Jacobson GA; Lee WL; Narkowicz CK; Vervaart P; Dargaville PA
Year: 2010

Pilot Study of Gene Expression & Protein Regulation in Barrett's Oesophagus and Oesophageal Adenocarcinoma (2009)$8,761

Funding: Clifford Craig Foundation ($8,761)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Jacobson GA; Rajendra S; Snow ET; Ball MJ
Year: 2009

Drug Discovery, Biotechnology and Bridging the Gap using an Intermediary: Pilot Application to Novel Flavonoids with Potential to Reduce Cardiovascular Disease Risk (2009)$19,799

Funding: University of Tasmania ($19,799)
Scheme: Grant-Cross Theme
Administered By: University of Tasmania
Research Team: Jacobson GA; Geraghty DP; Narkowicz CK; Hilder EF
Year: 2009

Business Competition Grant - School of Pharmacy (2008)$25,000

Funding: University of Tasmania ($25,000)
Scheme: Grant-Business Competition
Administered By: University of Tasmania
Research Team: Jacobson GA; Narkowicz CK
Year: 2008

R-Salbutamol dissolution from fish feed pellets (2007)$3,800

Funding: Stirling Products Limited ($3,800)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2007

Quantitative analysis of R-Salbutamol in feed samples (2007)$4,720

Funding: Stirling Products Limited ($4,720)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2007

Quantitative analysis of R-Salbutamol in pig muscle and liver: supplementation trial (2007)$6,480

Funding: Stirling Products Limited ($6,480)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2007

R, S-Salbutamol in chicken feed pellets (2007)$1,750

Funding: Stirling Products Limited ($1,750)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2007

Microsporum screening of algal extract formulation (2007)$1,700

Funding: Castella Research Pty Ltd ($1,700)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2007

Donation - Asthma Foundation of Tasmania PhD Scholarship for Kwang Choon Yee (2006 - 2009)$26,914

Funding: Donation via University of Tasmania Foundation ($26,914)
Scheme: Donation - Individual
Administered By: University of Tasmania
Research Team: Jacobson GA
Period: 2006 - 2009

Salbutamol Enantiomers in Delta-7 Mouse Plasma, Muscle and Brain- PK Range Study (2006)$3,360

Funding: Spinal Muscular Atrophy Foundation ($3,360)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2006

Hyphenated Capillary Electrophoresis-Mass Spectrometer Facility (2006)$262,706

Funding: Australian Research Council ($262,706)
Scheme: Grant-Linkage Infrastructure
Administered By: University of Tasmania
Research Team: Haddad PR; Clark MG; Reid JB; Bowie AR; Bowman JP; Ross JJ; Breadmore MC; McMeekin TA; Hilder EF; Guijt RM; Shellie RA; Jacobson GA
Year: 2006
Grant Reference: LE0668471

Analysis of the Essential Oil of Kunzea Ambigua and Screening Formulation for Antibacterial and Antifungal Activities (2006 - 2008)$54,546

Funding: Armstrong Pharmacy ($54,546)
Scheme: Grant-Student Research
Administered By: University of Tasmania
Research Team: Jacobson GA; Narayana AK
Period: 2006 - 2008

A Randomised Trial of Kunzea Oil in Comparison with Amorofline 5% Solution Nail Lacquer for the Treatment of Dermatophytic Toenail Onychomycoses (2006 - 2008)$88,875

Funding: AgriFutures ($88,875)
Scheme: Grant-Research Priorities Program
Administered By: University of Tasmania
Research Team: Jacobson GA; Peterson GM
Period: 2006 - 2008

Deslorelin implant analysis: effect of e-beam sterilisation (2005)$4,440

Funding: Castella Research Pty Ltd ($4,440)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2005

Deslorelin implant analysis: used implants #2 (2005)$3,320

Funding: Castella Research Pty Ltd ($3,320)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2005

Ceftiofur analysis in bovine serum (2004)$11,730

Funding: Castella Research Pty Ltd ($11,730)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2004

Deslorelin in plasma by LC-MS: methos development (2004)$5,000

Funding: Castella Research Pty Ltd ($5,000)
Scheme: Consultancy
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2004

Pharmacoproteomic Investigation of Barrett's Oesophagus and Proton Pump Inhibitor Therapy (2004)$6,364

Funding: Royal Hobart Hospital Research Foundation ($6,364)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Jacobson GA; Lord RJ; Chung S
Year: 2004

Tasmania: A Selenium-deficient State? A Population-based Assessment of Selenium Status (2003)$17,273

Funding: Royal Hobart Hospital Research Foundation ($17,273)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Peterson GM; Jacobson GA; Ball MJ; Vial JH
Year: 2003

Stereoselective Metabolism of Salbutamol as a Determinant of the Response in Acute Asthma (2002)$4,000

Funding: Royal Hobart Hospital Research Foundation ($4,000)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2002

Cancer Prevention in Barrett's Oesophagus: Celecoxib and In Vivo Assessment of COX-2 Expression in Metaplastic and Dysplastic Oesophageal Epithelium (2002)$7,824

Funding: Royal Hobart Hospital Research Foundation ($7,824)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Jacobson GA
Year: 2002

Tasmania: a selenium-deficient state? (2002)$16,000

Funding: University of Tasmania ($16,000)
Scheme: Grant-Institutional Research Scheme
Administered By: University of Tasmania
Research Team: Peterson GM; Jacobson GA; Townsend AT; Ball MJ; Vial JH; Davies NW
Year: 2002

Risk Factors for Upper Limb Fractures in Adolescence (1999 - 2000)$165,040

Funding: National Health & Medical Research Council ($165,040)
Scheme: Grant-MRC Project
Administered By: University of Tasmania
Research Team: Jones G; Morley R; Jacobson GA
Period: 1999 - 2000
Grant Reference: 990042

Risk Factors for Upper Limb Fractures in Adolescence (1998)$7,002

Funding: Clifford Craig Medical Research Trust/UTAS ($7,002)
Scheme: Grant-Collaborative
Administered By: University of Tasmania
Research Team: Jones G; Morley R; Jacobson GA
Year: 1998

Research Supervision

Dr Jacobson has supervised 8 RHD graduands, and is currently supervising 4 RHD students. Opportunities for PhD supervision and scholarships may arise in the area of beta2-agonists/muscle related projects for students with demonstrated excellence in sports science, muscle and cardiorespiratory physiology or drug testing background.

Current

Completed

Current

Degree	Title	Commenced
PhD	Effects of Insulin on Muscle Performance, Exercise Recovery and the Interrelationship with Beta2-Agonists Drugs	2020
PhD	Exploring the Role of Adrenergic Signalling and Therapeutic Effects of 2 - Adrenergic Agonists in Traumatic Brain Injury	2021

Completed

Degree	Title	Completed
PhD	Cognitive Outcomes Associated with Long-Term, Recreational Cannabis Use Candidate: Monica Mellefont	2021
PhD	Assessment of Citrus Bioflavonoid and Phytosterol Supplements for Dipeptidyl Peptidase-4 Inhibitory Activity Candidate: Ankit Gupta	2020
PhD	Role of Adipose Tissue Microvascular Blood Flow in Type 2 Diabetes Candidate: Donghua Hu	2018
PhD	Biological and Behavioural Markers of Smoking Reduction Candidate: Wenying Lu	2017
PhD	Towards Understanding the Mechanism of Clioquinol Neurotoxicity Candidate: Jamuna Chhetri	2017
PhD	Application of Infra-Red Spectroscopy to the Evaluation of Biofilm Formation and Pathogenesis of Nontypeable Haemophilus influenzae Candidate: Najla Abdullah Obaid	2016
PhD	The Pharmaceutical and Nutraceutical Potential of the Halophytic Plant Carpobrotus rossii Candidate: Adam Douglas Pirie	2014
PhD	Factors Influencing the Performance and Documentation of Clinical Interventions by Australian Community Pharmacists Candidate: Mackenzie Williams	2013
PhD	Studies on the Use of Glycosaminoglycans for the Treatment of Alzheimer's Disease Candidate: Hao Cui	2012
PhD	The Pharmaceutical Potential of Compounds from Tasmanian Clematis Species Candidate: Fangming Jin	2012
PhD	Kunzea Oil: Investigation of Composition, Bioactivity and Therapeutic Potential Candidate: Jackson Thomas	2010
PhD	Pharmacogenetics and Chiral Aspects of Anti-Asthma Therapy Candidate: Kwang Choon Yee	2009
Masters	Extraction, Analysis, and Biological Screening of Callitris Species Essential Oils Candidate: Prince Ninan Philip	2009
PhD	Enoxaparin: Physicochemical Investigations into the Effects of Freezing and Heating Candidate: Rahul Prabhudas Patel	2008
Masters	Investigation of Chemical Components and Pharmaceutical Potential of Carpobrotus Species Candidate: Raghunath Reddy Vennavaram	2007